PARP1 and Alzheimer disease: Furthermore, exogenous treatment of AD patient-derived fibroblasts with NAD, which not only restores NAD+ levels but also inhibits PARP, decreased oxidative stress manifested as a rise in 8-Hydroxy-2′-deoxyguanosine (DNA oxidative damage) and mitochondrial ROS [143].